Back to Search
ANTHONY BOLTON, PHD
PHD
Psychiatry Physician
NPI: 1275653032IndividualAccepts Medicare
Specialties, Licenses & Credentials
Psychiatry PhysicianPrimary
Psychiatry & Neurology — Psychiatry
Code: 2084P0800X
0113678(NY)
CMS Specialties
PrimaryCLINICAL PSYCHOLOGIST
Education
OTHER
Class of 1991
Research & Publications (20)
A novel phospholipid-based drug formulation, VP025, modulates age- and LPS-induced microglial activity in the rat.
PMID 19609089·Neuroimmunomodulation·2009
7-preclinical
Trends in wood dust inhalation exposure in the UK, 1985-2005.
PMID 19602501·Ann Occup Hyg·2009
8-other
Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease.
PMID 19349823·Neurosurgery·2009
7-preclinical
The deficit in long-term potentiation induced by chronic administration of amyloid-beta is attenuated by treatment of rats with a novel phospholipid-based drug formulation, VP025.
PMID 19121379·Exp Gerontol·2009
7-preclinical
Treatment with phosphotidylglycerol-based nanoparticles prevents motor deficits induced by proteasome inhibition: implications for Parkinson's disease.
PMID 18817814·Behav Brain Res·2008
7-preclinical
Neuroprotective effects of novel phosphatidylglycerol-based phospholipids in the 6-hydroxydopamine model of Parkinson's disease.
PMID 18190522·Eur J Neurosci·2008
4-observational
The incidence of occupational skin disease as reported to The Health and Occupation Reporting (THOR) network between 2002 and 2005.
PMID 17596159·Br J Dermatol·2007
4-observational
Assigning exposure to pesticides and solvents from self-reports collected by a computer assisted personal interview and expert assessment of job codes: the UK Adult Brain Tumour Study.
PMID 16556747·Occup Environ Med·2006
4-observational
Utilization of a whole genome SNP panel for efficient genetic mapping in the mouse.
PMID 16461637·Genome Res·2006
7-preclinical
Serial autofluorescence imaging over two years following indocyanine green-assisted internal limiting membrane peel for macular hole.
PMID 16181288·Clin Exp Ophthalmol·2005
5-case
Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study.
PMID 15963092·Br J Clin Pharmacol·2005
3-trial
Biologic effects and basic science of a novel immune-modulation therapy.
PMID 15925561·Am J Cardiol·2005
6-review
Evidence of an anti-inflammatory role for Vasogen's immune modulation therapy.
PMID 15785113·Neuroimmunomodulation·2005
7-preclinical
Role of interleukin-4 in regulation of age-related inflammatory changes in the hippocampus.
PMID 15615726·J Biol Chem·2005
7-preclinical
Use of the surface proteins GapC and Mig of Streptococcus dysgalactiae as potential protective antigens against bovine mastitis.
PMID 15284888·Can J Microbiol·2004
7-preclinical
Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.
PMID 14605865·Cancer Chemother Pharmacol·2004
3-trial
Insurance-based advantages for subordinate co-foundresses in a temperate paper wasp.
PMID 12908983·Proc Biol Sci·2003
7-preclinical
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
PMID 12637609·N Engl J Med·2003
3-trial
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
PMID 14534335·N Engl J Med·2003
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 464 MAIN ST, SUITE B
PORT JEFFERSON, NY 11777 - Phone
- (631) 331-4377
Quick Facts
- NPI
- 1275653032
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 35
- Publications
- 20
Are you this provider?
Claim Your Profile